TY - JOUR
T1 - Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia
AU - Al-Khabori, Murtadha
AU - Minden, Mark D.
AU - Yee, Karen W.L.
AU - Gupta, Vikas
AU - Schimmer, Aaron D.
AU - Schuh, Andre C.
AU - Xu, Wei
AU - Brandwein, Joseph M.
PY - 2010/1
Y1 - 2010/1
N2 - All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed. From 1990 to 2000, 40 patients were treated with a variety of adult-based ALL regimens. From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber Cancer Institute), was used as the standard regimen for all patients (n=32). The two groups (DFCI and non-DFCI) had comparable baseline characteristics. Complete response rates were not significantly different between the DFCI- and non-DFCI-treated groups. The 3-year relapse free survival (RFS) and overall survival (OS) were significantly higher in the DFCI-treated group (p<0.0001 and p=0.0003, respectively). On multivariate analysis, the treatment group (DFCI vs. non-DFCI) was the major prognostic factor influencing both RFS and OS. The results provide evidence supporting the superior efficacy of asparaginase-intensive pediatric-based regimens for adults with T-ALL.
AB - All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed. From 1990 to 2000, 40 patients were treated with a variety of adult-based ALL regimens. From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber Cancer Institute), was used as the standard regimen for all patients (n=32). The two groups (DFCI and non-DFCI) had comparable baseline characteristics. Complete response rates were not significantly different between the DFCI- and non-DFCI-treated groups. The 3-year relapse free survival (RFS) and overall survival (OS) were significantly higher in the DFCI-treated group (p<0.0001 and p=0.0003, respectively). On multivariate analysis, the treatment group (DFCI vs. non-DFCI) was the major prognostic factor influencing both RFS and OS. The results provide evidence supporting the superior efficacy of asparaginase-intensive pediatric-based regimens for adults with T-ALL.
KW - Acute lymphoblastic leukemia
KW - Chemotherapeutic approaches
KW - Prognostication
UR - http://www.scopus.com/inward/record.url?scp=74949134816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74949134816&partnerID=8YFLogxK
U2 - 10.3109/10428190903388376
DO - 10.3109/10428190903388376
M3 - Article
C2 - 20017600
AN - SCOPUS:74949134816
SN - 1042-8194
VL - 51
SP - 61
EP - 65
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -